Evidence map›Paper›PMID 40707990›Full record

ArticleMicrobiome2025

Microbiome-derived reactivation of mycophenolate explains variations in enterohepatic recirculation in kidney transplant recipients.

Ole Martin Drevland, Eric J de Muinck, Pål Trosvik, Marta Hammerstad, Kine Eide Kvitne, Karsten Midtvedt, Anders Åsberg, Ida Robertsen

Abstract read
In one paragraph

Article in Microbiome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ole Martin DrevlandSection for Pharmacologyand, Pharmaceutical Biosciences, Department of Pharmacy , University of Oslo, Oslo, Norway. oledre@uio.no.
Eric J de MuinckSection for Pharmacologyand, Pharmaceutical Biosciences, Department of Pharmacy , University of Oslo, Oslo, Norway.
Pål TrosvikCentre for Ecological and Evolutionary Synthesis, Department of Biosciences, University of Oslo, Oslo, Norway.
Marta HammerstadSection for Biochemistry and Molecular Biology, Department of Biosciences, University of Oslo, Oslo, Norway.
Kine Eide KvitneSection for Pharmacologyand, Pharmaceutical Biosciences, Department of Pharmacy , University of Oslo, Oslo, Norway.
Karsten MidtvedtDepartment of Transplantation Medicine, Oslo University Hospital, Oslo, Norway.
Anders ÅsbergSection for Pharmacologyand, Pharmaceutical Biosciences, Department of Pharmacy , University of Oslo, Oslo, Norway.
Ida RobertsenSection for Pharmacologyand, Pharmaceutical Biosciences, Department of Pharmacy , University of Oslo, Oslo, Norway. ida.robertsen@farmasi.uio.no.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe pivotal role of microbes in drug metabolism is increasingly recognized, as variation in the gut microbiome composition between individuals has been shown to impact systemic drug exposure, efficacy and toxicity. Mycophenolate mofetil (MMF) is a cornerstone in immunosuppressive therapy following solid organ transplantation. However, dosing and tolerance are challenged by significant pharmacokinetic variability among patients, largely due to variable degrees of enterohepatic recirculation of mycophenolic acid (MPA), the active moiety of MMF. It is hypothesized that the variability in MPA recirculation is driven by gut microbiome-derived β-glucuronidase (β-GUS) mediated cleavage of MPA-glucuronide (MPAG) excreted in the bile. Here, we investigated the bidirectional interaction between MPA and the gut microbiome in kidney transplant recipients, using a combination of in vivo and in vitro data.

resultsWe compared the fecal microbiomes of kidney transplant recipients (n = 21) both pre- and post-transplantation to healthy individuals (n = 15) using shotgun metagenomic sequencing. We also determined the individual microbiome-derived reactivation rate of MPAG to MPA and show a strong positive correlation between this reactivation rate and the degree of MPA enterohepatic recirculation in vivo. Through metagenomic analysis, the reactivation rate of MPA was linked to specific gut microbial species. In particular, specific β-GUS gene variants associated with Faecalibacterium prausnitzii showed a strong impact on the conversion of MPAG to MPA. Furthermore, our study confirmed a significant shift in microbial composition post-transplantation and revealed notable fluctuations in species such as F. prausnitzii and Akkermansia muciniphila across different time points after transplantation. Lastly, we provide evidence that the microbiome-derived reactivation rate of MPA is linked to specific beta-glucuronidase alleles.

conclusionsWe highlight for the first time that the ex vivo determined reactivation rate of MPA explains the variation of enterohepatic recirculation, emphasizing the important role of F. prausnitzii in this process. More broadly, our findings suggest that the gut microbiome significantly influences the degree of enterohepatic recirculation of MPA, providing valuable insights that could be relevant for optimizing individualized immunosuppressive drug dosing in transplant patients. Video Abstract.

Indexed as

Enterohepatic CirculationGastrointestinal MicrobiomeImmunosuppressive AgentsKidney TransplantationMycophenolic AcidAdultFecesFemaleGlucuronidaseGlucuronidesHumansMaleMetagenomicsMiddle AgedTransplant RecipientsGlucuronidaseGlucuronidesImmunosuppressive AgentsMycophenolic Acidmycophenolic acid glucuronideEnterohepatic recirculationFaecalibacterium prausnitziiGut microbiomeMycophenolateReactivationβ-glucuronidase

Identifiers

PMID40707990
PMCPMC12291295

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.